This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Recurrent sebaceous gland carcinoma

Recurrent sebaceous gland carcinoma
Reviewed by Rina Bhatt

7 December 2020 | Rina Bhatt | EYE - Pathology, EYE - Oncology
Share This

In this retrospective case review study, authors report their outcomes in management of recurrent sebaceous gland carcinoma (SGC) and propose a graded protocol to manage these entities. All consecutive cases of SGC from January 2004 to December 2017 at the Royal Hallamshire Hospital, Sheffield were assessed. They included cases of SGC with confirmed recurrence during the study period and excluded cases who had initial or subsequent management at different centres and those left to follow-up. Of the 62 cases with eyelid SGC diagnosed between January 2004-December 2017, 10 were included in the study based on the inclusion criteria. The most common presenting symptom was appearance of an eyelid mass (n=5) or irritation (n=5). Associated sign of eyelid margin thickening was noted in five cases. The mean time interval between initial excision and recurrence was 37 months (range 14-84 months). Metastatic disease was diagnosed in two patients. Patients received full thickness biopsy +/-conjunctival mapping biopsies and adjuvant cryotherapy +/- intralesional or topical Interferon alpha-2a. Four patients underwent orbital exenteration due to inadequate disease control, invasive SGC with extensive non-resectable pagetoid spread, pagetoid in situ SGC causing painful blind eye due to limbal stem cell failure. Two of 10 patients developed metastases. Two patients passed away during study period one with evidence of metastasis and another not related to the tumour. Based on their results, the authors propose close follow-up for first two years and total follow-up of up to 10 years to ensure no local recurrence after initial diagnosis with low threshold for rebiopsy and adjuvant therapy if required. They also propose globe preserving local treatment options and exenteration surgery to be considered in severe cases of in situ or invasive disease.

Management of recurrent sebaceous gland carcinoma.
McGrath LA, Currie ZI, Mudhar HS, et al.
EYE
2020;34:1685-92.
Share This
CONTRIBUTOR
Rina Bhatt

Wolverhampton Eye Infirmary, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency